251 related articles for article (PubMed ID: 30387865)
1. Effects of Conversion From Calcineurin Inhibitors to Sirolimus or Everolimus on Renal Function and Possible Mechanisms in Liver Transplant Recipients.
Tsai KF; Li LC; Hsu CN; Lin CC; Lin YH; Cheng YF; Wang CC; Chen CL
J Clin Pharmacol; 2019 Mar; 59(3):326-334. PubMed ID: 30387865
[TBL] [Abstract][Full Text] [Related]
2. Influence of conversion from calcineurin inhibitors to everolimus on fibrosis, inflammation, tubular damage and vascular function in renal transplant patients.
Alpay N; Ozkok A; Caliskan Y; Akagun T; Cinar SA; Deniz G; Sariyar M; Yildiz A
Clin Exp Nephrol; 2014 Dec; 18(6):961-7. PubMed ID: 24515306
[TBL] [Abstract][Full Text] [Related]
3. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
Nashan B; Schemmer P; Braun F; Dworak M; Wimmer P; Schlitt H
Trials; 2015 Mar; 16():118. PubMed ID: 25873064
[TBL] [Abstract][Full Text] [Related]
5. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
[TBL] [Abstract][Full Text] [Related]
6. Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate.
Arora S; Gude E; Sigurdardottir V; Mortensen SA; Eiskjær H; Riise G; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Aukrust P; Solbu D; Iversen M; Gullestad L
J Heart Lung Transplant; 2012 Mar; 31(3):259-65. PubMed ID: 22333403
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil gelatinase-associated lipocalin (NGAL) in heart transplant recipients after conversion to everolimus therapy.
Stypmann J; Fobker M; Rosing K; Engelen M; Gunia S; Dell'Aquila AM; Nofer JR
J Cardiol; 2015 Oct; 66(4):347-52. PubMed ID: 25583090
[TBL] [Abstract][Full Text] [Related]
8. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
9. Renal recovery after conversion to an everolimus-based immunosuppression in early and late heart transplant recipients: a 12-month analysis.
Michel S; Bigdeli AK; Hagl C; Meiser B; Kaczmarek I
Exp Clin Transplant; 2013 Oct; 11(5):429-34. PubMed ID: 24128136
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study.
Lehner F; Budde K; Zeier M; Wüthrich RP; Reinke P; Eisenberger U; Mühlfeld A; Arns W; Stahl R; Heller K; Witzke O; Wolters HH; Suwelack B; Klehr HU; Stangl M; Hauser IA; Nadalin S; Porstner M; May C; Paulus EM; Sommerer C;
Transpl Int; 2014 Nov; 27(11):1192-204. PubMed ID: 25070687
[TBL] [Abstract][Full Text] [Related]
11. Clinical Experience of Late Conversion From Antimetabolites With Standard Exposure Calcineurin Inhibitors to Everolimus With Calcineurin Inhibitor Minimization in Stable Kidney Transplant Recipients With Good Renal Function.
Uchida J; Iwai T; Kuwabara N; Kabei K; Nishide S; Yamasaki T; Naganuma T; Kumada N; Takemoto Y; Nakatanti T
Transplant Proc; 2016 Apr; 48(3):775-80. PubMed ID: 27234734
[TBL] [Abstract][Full Text] [Related]
12. Predictors of long-term renal function after conversion to proliferation signal inhibitors in long-term heart transplant recipients.
González-Vilchez F; de Prada JA; Castrillo C; Canteli A; Llano MF; Martín-Durán R
J Heart Lung Transplant; 2011 May; 30(5):552-7. PubMed ID: 21212001
[TBL] [Abstract][Full Text] [Related]
13. Fibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs. calcineurin inhibitors.
Villamil FG; Gadano AC; Zingale F; Perez R; Gil O; Yantorno S; Mastai R; Cairo FO; Otero AB; Dong G; Lopez P;
Liver Int; 2014 Nov; 34(10):1513-21. PubMed ID: 25453134
[TBL] [Abstract][Full Text] [Related]
14. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J
Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
[TBL] [Abstract][Full Text] [Related]
16. Treatment with everolimus is associated with a procoagulant state.
Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of conversion to sirolimus monotherapy after liver transplant.
Uhlmann D; Weber T; Ludwig S; Ludwig B; Bartels M; Hauss J; Jonas S; Witzigmann H
Exp Clin Transplant; 2012 Feb; 10(1):30-8. PubMed ID: 22309417
[TBL] [Abstract][Full Text] [Related]
18. Everolimus and long-term decline in renal function after liver transplantation: real-life experience with measured GFR.
Åberg F; Berntsson J; Herlenius G; Castedal M; Bennet W
Scand J Gastroenterol; 2020 Jun; 55(6):718-724. PubMed ID: 32479116
[TBL] [Abstract][Full Text] [Related]
19. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.
Holdaas H; Rostaing L; Serón D; Cole E; Chapman J; Fellstrøm B; Strom EH; Jardine A; Midtvedt K; Machein U; Ulbricht B; Karpov A; O'Connell PJ;
Transplantation; 2011 Aug; 92(4):410-8. PubMed ID: 21697773
[TBL] [Abstract][Full Text] [Related]
20. Conversion from everolimus with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in kidney transplant recipients: a randomized, open-label multicenter study.
Albano L; Alamartine E; Toupance O; Moulin B; Merville P; Rerolle JP; Tetaz R; Moal MC; Kamar N; Legendre C; Quéré S; Di Giambattista F; Terpereau A; Dantal J
Ann Transplant; 2012; 17(1):58-67. PubMed ID: 22466910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
